What is Ligand Pharmaceuticals's EV / EBITDA?

Ligand Pharmaceuticals (LGND) reported EV / EBITDA of 30.3× in Q1 2026.

What is the long-term trend for Ligand Pharmaceuticals's EV / EBITDA?

Over 5 years (2020 to 2025), Ligand Pharmaceuticals's EV / EBITDA has grown at a 12.9% compound annual growth rate (CAGR), from 25.9× to 47.5×.

What does EV / EBITDA mean?

Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ligand Pharmaceuticals LGND EV / EBITDA

EV / EBITDA at other companies

Royalty PharmaRPRX

13.9×+1.7×

RevvityRVTY

16.7×-2.2×

Roivant SciencesROIV

1.8×—

Kiniksa Pharmaceuticals International, plcKNSA

36.9×—

ALN

Alnylam PharmaceuticalsALNY

52.6×—

Bristol-Myers SquibbBMY

12×+0.4×

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Calculated from Ligand Pharmaceuticals’s reported figures.

enterprise value/ebitda=30.3×

Based on the most recent quarter.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's EV / EBITDA?: Ligand Pharmaceuticals (LGND) reported EV / EBITDA of 30.3× in Q1 2026.
What is the long-term trend for Ligand Pharmaceuticals's EV / EBITDA?: Over 5 years (2020 to 2025), Ligand Pharmaceuticals's EV / EBITDA has grown at a 12.9% compound annual growth rate (CAGR), from 25.9× to 47.5×.
What does EV / EBITDA mean?: Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.